Dr. Reddy's Laboratories Limited has announced the allotment of 10,275 equity shares to eligible employees under its Employee Stock Options Plans (ESOPs) on March 12, 2026. The pharmaceutical company issued this disclosure in compliance with Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

Share Allotment Details

The company allotted the equity shares pursuant to the exercise of stock options by employees under two established schemes. The allotment covers shares under both Dr. Reddy's Employees Stock Options Scheme, 2002 and Dr. Reddy's Employees ADR Stock Options Scheme, 2007.

Updated Share Capital Structure

Following this allotment, Dr. Reddy's Laboratories' share capital structure has been updated to reflect the additional equity shares issued to employees.

The company noted a difference of 1,000 shares between issued and paid-up capital due to forfeited shares of Re. 1/- each in September 1988 on account of non-payment of allotment money.

Regulatory Compliance and Share Characteristics

The newly allotted shares are identical in all respects to the existing equity shares and rank pari passu with them. The shares carry no lock-in restrictions and are eligible for immediate trading. The company has listed its shares on multiple exchanges including BSE Limited, National Stock Exchange of India Limited, New York Stock Exchange Inc. (ADRs), and NSE IFSC Limited (ADRs).

The ESOP schemes under which these shares were allotted were originally established under the erstwhile SEBI (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999, and now comply with the provisions of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The disclosure was signed by K Randhir Singh, Company Secretary, Compliance Officer & Head-CSR.

Dr. Reddy's Laboratories Limited has announced a significant leadership change with the elevation of Mr. M S Madhu Sundar to the position of Global Head of Quality and PV. The pharmaceutical company's Board of Directors approved this appointment on March 10, 2026, based on the recommendation of the Nomination, Governance and Compensation Committee.

Leadership Elevation Details

The appointment becomes effective from April 1, 2026, with Madhu Sundar transitioning from his current role as Head Global Manufacturing FTO Oral Solid Dosages (OSD) & Operational Excellence (OE). As part of this elevation, he will also serve as Senior Management Personnel and be inducted as a Member of Management Council.

Professional Background

Madhu Sundar brings extensive experience to his new role, currently serving as the Head of Formulation Manufacturing of 7 OSD units within the Global Manufacturing Organization. He also leads the Operations Excellence program of the Global Manufacturing Organization. His educational credentials include a post-graduate degree in Chemistry and an M. Tech degree in advanced analytical chemistry from IIT Delhi.

With 28 years of industrial experience, Madhu Sundar has handled diverse assignments across manufacturing, quality management, regulatory affairs, and supply chain operations. He joined Dr. Reddy's Laboratories in October 2017 as a site head and has progressively assumed positions of increasing responsibility within the organization. He has been serving in his current role since December 2023.

Additional Senior Management Changes

The company has also announced role changes for several other senior management personnel, all effective from April 1, 2026:

Regulatory Compliance

The announcement was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was communicated to multiple stock exchanges including the National Stock Exchange of India Ltd., BSE Limited, New York Stock Exchange Inc., and NSE IFSC Ltd. on March 10, 2026.

These leadership changes reflect the company's strategic focus on strengthening its management structure across key operational areas including quality, manufacturing, and product development functions.